CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality pharmaceutical company will lead to a definitive accord later this year.
ReNeuron signs retinal stem cell exclusivity agreement
Quick facts: ReNeuron Group PLC
Price: 138.75 GBX
Market Cap: £44.17 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE